Savara (NASDAQ:SVRA) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Savara (NASDAQ:SVRA) released its earnings results on Tuesday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), FiscalAI reports.

Savara Stock Down 2.8%

Shares of Savara stock traded down $0.16 during trading on Tuesday, reaching $5.57. 1,263,637 shares of the company traded hands, compared to its average volume of 1,622,296. The firm has a market capitalization of $1.14 billion, a PE ratio of -9.95 and a beta of 0.29. Savara has a 1-year low of $2.43 and a 1-year high of $7.01. The company has a 50 day moving average price of $5.63 and a 200-day moving average price of $5.50. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on SVRA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Oppenheimer initiated coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Savara in the fourth quarter worth approximately $396,000. Invesco Ltd. increased its holdings in shares of Savara by 302.1% during the fourth quarter. Invesco Ltd. now owns 688,595 shares of the company’s stock valued at $4,152,000 after acquiring an additional 517,329 shares in the last quarter. KVP Capital Advisors LP acquired a new position in shares of Savara during the fourth quarter worth approximately $3,650,000. Voloridge Investment Management LLC acquired a new position in shares of Savara during the fourth quarter worth approximately $520,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Savara by 1.2% in the 4th quarter. Wellington Management Group LLP now owns 2,674,931 shares of the company’s stock worth $16,130,000 after purchasing an additional 30,931 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.